JDP Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From JDP Therapeutics, Inc.
Keeping Track: US FDA Approves Esperoct, Tightens Chantix Label, Starts Review Of Alder’s CGRP Candidate
The latest drug development news and highlights from our US FDA Performance Tracker.
Two Phase III studies, PEARL 1 and PEARL 2, will compare Novartis's candidate anti-IgE antibody with the previous generation anti-IgE MAb, Xolair, for the treatment of chronic spontaneous urticaria.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
JDP Therapeutics Inc. is working to reformulate an off-patent oral drug into an injectable form that will treat the peripheral, non-life-threatening symptoms of acute allergic reactions to substances such as peanuts and seafood. The benefit envisioned? Fewer side effects than the IV Benadryl currently given to relieve body swelling and itching.
- Specialty Pharmaceuticals
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.